Answer
With Vocabria (cabotegravir) plus rilpivirine injections, headache and fever (including feeling hot or increased body temperature) are very common (≥1 in 10); most fever events occur within one week of injections, and frequencies reflect all reported events, not only those considered possibly treatment-related.
Sources for this answer
- Vocabria 600 mg prolonged-release suspension for injectionViiV Healthcare UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked